St. Jude Children's Research Hospital researchers report that maximizing the
dose of hydroxyurea increased levels of fetal hemoglobin and reduced the odds of hospitalizations for young sickle cell anemia patients
In an accompanying editorial, Debra L. Weiner and Carlo Brugnara of Harvard Medical School call for increased
use of hydroxyurea.
The original
study of hydroxyurea's effects, which was randomized, double - blind and tested for the placebo effect, took place between 1992 and 1995.
Feng said that breakage patterns at different
subsets of the hydroxyurea - induced genes were also observed in wild type cells and checkpoint - deficient mutant cells with unstable replication forks.
Examining the characteristics and
beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.
Rather than calculating a standard dose
of hydroxyurea based on patients» weight, researchers used a dose - escalation approach to determine the maximum tolerated dose for each of the 230 St. Jude patients enrolled in the study.
For this study, patients received a starting
dose of hydroxyurea that was escalated in a stepwise manner until patients reached a predetermined maximum dose (either 35 milligrams per kilogram daily or 2,000 milligrams daily) or experienced mild neutropenia.